المؤلفون: Miller A., Stone E.

مصطلحات الفهرس: lung cancer/di [Diagnosis], cancer chemotherapy, cancer immunotherapy, cancer mortality, cancer radiotherapy, cancer research, cancer risk, cancer screening, editorial, human, lung cancer/ep [Epidemiology], lung cancer/rt [Radiotherapy], lung cancer/su [Surgery], multidisciplinary team, non small cell lung cancer/dt [Drug Therapy], priority journal, publishing, risk factor, sex difference, smoking, video assisted thoracoscopic surgery, antineoplastic agent/dt [Drug Therapy], Editorial

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28483
Respirology
Click here for full text options
LibKey Link

المؤلفون: Miller A., Stone E.

مصطلحات الفهرس: lung cancer/di [Diagnosis], cancer chemotherapy, cancer immunotherapy, cancer mortality, cancer radiotherapy, cancer research, cancer risk, cancer screening, editorial, human, lung cancer/ep [Epidemiology], lung cancer/rt [Radiotherapy], lung cancer/su [Surgery], multidisciplinary team, non small cell lung cancer/dt [Drug Therapy], priority journal, publishing, risk factor, sex difference, smoking, video assisted thoracoscopic surgery, antineoplastic agent/dt [Drug Therapy], Editorial

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28483
Respirology
LibKey Link

المؤلفون: Onggo J., Parakh S., John T., Balasubramanian A., Gunjur A.

مصطلحات الفهرس: atezolizumab/dt [Drug Therapy], atezolizumab/pv [Special Situation for Pharmacovigilance], durvalumab/dt [Drug Therapy], durvalumab/pv [Special Situation for Pharmacovigilance], immune checkpoint inhibitor/ae [Adverse Drug Reaction], immune checkpoint inhibitor/dt [Drug Therapy], immune checkpoint inhibitor/pv [Special Situation for Pharmacovigilance], nivolumab/dt [Drug Therapy], nivolumab/pv [Special Situation for Pharmacovigilance], pembrolizumab/dt [Drug Therapy], pembrolizumab/pv [Special Situation for Pharmacovigilance], pneumonia/co [Complication], adult, aged, cancer patient, cancer staging, chemoradiotherapy, clinical trial (topic), drug fatality/si [Side Effect], drug safety, human, meta analysis, middle aged, non small cell lung cancer/dt [Drug Therapy], non small cell lung cancer/rt [Radiotherapy], odds ratio, pneumonia/si [Side Effect], review, systematic review, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/26855
Clinical Lung Cancer
LibKey Link

المؤلفون: Brown M.R., Vajdic C.M., Delaney G.P., Hong S., Hunt L., Webber K., Pearson S.-A., Van Leeuwen M.T., Luu S., Gurney H.

مصطلحات الفهرس: meta analysis, multiple myeloma/dt [Drug Therapy], observational study, oncology, ovary cancer/dt [Drug Therapy], peer review, phase 2 clinical trial (topic), phase 3 clinical trial (topic), priority journal, prostate cancer/dt [Drug Therapy], QT prolongation/si [Side Effect], randomized controlled trial (topic), review, systematic review, venous thromboembolism/si [Side Effect], abiraterone/ae [Adverse Drug Reaction], abiraterone/ct [Clinical Trial], abiraterone/dt [Drug Therapy], aflibercept/ae [Adverse Drug Reaction], aflibercept/ct [Clinical Trial], androgen receptor/ec [Endogenous Compound], axitinib/ae [Adverse Drug Reaction], axitinib/ct [Clinical Trial], bevacizumab/ae [Adverse Drug Reaction], bevacizumab/ct [Clinical Trial], bevacizumab/dt [Drug Therapy], cediranib/ae [Adverse Drug Reaction], cediranib/ct [Clinical Trial], cetuximab/ae [Adverse Drug Reaction], cetuximab/ct [Clinical Trial], cytochrome P450 family 17/ec [Endogenous Compound], enzalutamide/ae [Adverse Drug Reaction], enzalutamide/ct [Clinical Trial], enzalutamide/dt [Drug Therapy], epidermal growth factor receptor 2/ec [Endogenous Compound], estrogen receptor alpha/ec [Endogenous Compound], estrogen receptor beta/ec [Endogenous Compound], Flt3 ligand/ec [Endogenous Compound], lenalidomide/ae [Adverse Drug Reaction], lenalidomide/ct [Clinical Trial], lenalidomide/dt [Drug Therapy], nintedanib/ae [Adverse Drug Reaction], nintedanib/ct [Clinical Trial], panitumumab/ae [Adverse Drug Reaction], panitumumab/ct [Clinical Trial], pazopanib/ae [Adverse Drug Reaction], pazopanib/ct [Clinical Trial], platelet derived growth factor alpha receptor/ec [Endogenous Compound], platelet derived growth factor beta receptor/ec [Endogenous Compound], protein Ret/ec [Endogenous Compound], Raf protein/ec [Endogenous Compound], ramucirumab/ae [Adverse Drug Reaction], ramucirumab/ct [Clinical Trial], sorafenib/ae [Adverse Drug Reaction], sorafenib/ct [Clinical Trial], sorafenib/dt [Drug Therapy], sunitinib/ae [Adverse Drug Reaction], sunitinib/ct [Clinical Trial], tamoxifen/ae [Adverse Drug Reaction], tamoxifen/ct [Clinical Trial], tamoxifen/dt [Drug Therapy], thalidomide/ae [Adverse Drug Reaction], thalidomide/ct [Clinical Trial], thalidomide/dt [Drug Therapy], transcription factor/ec [Endogenous Compound], trastuzumab/ae [Adverse Drug Reaction], trastuzumab/ct [Clinical Trial], trastuzumab/dt [Drug Therapy], unclassified drug, vandetanib/ae [Adverse Drug Reaction], vandetanib/ct [Clinical Trial], vandetanib/dt [Drug Therapy], vasculotropin A/ec [Endogenous Compound], vasculotropin receptor 1/ec [Endogenous Compound], vasculotropin receptor 3/ec [Endogenous Compound], cytochrome P450 family 17a1/ec [Endogenous Compound], lymphoid transcription factor ikzf1/ec [Endogenous Compound], lymphoid transcription factor ikzf3/ec [Endogenous Compound], molecularly targeted therapy, arterial thromboembolism/si [Side Effect], breast cancer/dt [Drug Therapy], cardiology, cardiotoxicity/si [Side Effect], castration resistant prostate cancer/dt [Drug Therapy], clinician, Cochrane Library, cohort analysis, congestive heart failure/si [Side Effect], controlled study, drug megadose, Embase, female, general practice, heart left ventricle ejection fraction, human, hypertension/si [Side Effect], low drug dose, lung cancer/dt [Drug Therapy], male, Medline, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/27204
JNCI Cancer Spectrum
LibKey Link

المؤلفون: Atkinson V., Haydon A., Millward M., Begbie S., Brown M., Markman B., Patterson W., Hill A., Horvath L., Nagrial A., Richardson G., Jackson C., Friedlander M., Parente P., Tran B., Wang L., Chen Y., Tang Z., Huang W., Wu J., Zeng D., Luo L., Solomon B., Desai J., Gan H., Barrow C., Jameson M.

مصطلحات الفهرس: endometrium cancer/di [Diagnosis], endometrium cancer/dt [Drug Therapy], endometrium cancer/et [Etiology], enzyme inhibition, fatigue/si [Side Effect], female, fever/si [Side Effect], gastroesophageal reflux/si [Side Effect], glossodynia/si [Side Effect], hand foot syndrome/si [Side Effect], headache/si [Side Effect], human, hyperkeratosis/si [Side Effect], hypertension/si [Side Effect], hypomagnesemia/si [Side Effect], hypophosphatemia/si [Side Effect], hypotension/si [Side Effect], insomnia/si [Side Effect], intestine obstruction/si [Side Effect], intestine perforation/si [Side Effect], lethargy/si [Side Effect], limb pain/si [Side Effect], major clinical study, male, maximum plasma concentration, maximum tolerated dose, melanoma/di [Diagnosis], melanoma/dt [Drug Therapy], melanoma/et [Etiology], multiple cycle treatment, muscle spasm/si [Side Effect], musculoskeletal chest pain/si [Side Effect], myalgia/si [Side Effect], nausea/si [Side Effect], neutropenia/si [Side Effect], non small cell lung cancer/di [Diagnosis], non small cell lung cancer/dt [Drug Therapy], non small cell lung cancer/et [Etiology], oncogene N ras, oropharynx pain/si [Side Effect], ovary cancer/di [Diagnosis], ovary cancer/dt [Drug Therapy], ovary cancer/et [Etiology], palmoplantar keratoderma/si [Side Effect], pericardial effusion/si [Side Effect], phase 1 clinical trial, photosensitivity/si [Side Effect], pleura effusion/si [Side Effect], positron emission tomography-computed tomography, priority journal, progression free survival, pruritus/si [Side Effect], QT prolongation/si [Side Effect], rash/si [Side Effect], sepsis/si [Side Effect], side effect/si [Side Effect], skin defect/si [Side Effect], skin hypertrophy/si [Side Effect], solid malignant neoplasm, thrombocytopenia/si [Side Effect], thrush/si [Side Effect], thyroid cancer/di [Diagnosis], thyroid cancer/dt [Drug Therapy], thyroid cancer/et [Etiology], thyroid papillary carcinoma/di [Diagnosis], thyroid papillary carcinoma/dt [Drug Therapy], thyroid papillary carcinoma/et [Etiology], treatment duration, upper abdominal pain/si [Side Effect], upper respiratory tract infection/si [Side Effect], urinary tract infection/si [Side Effect], vomiting/si [Side Effect], xerostomia/si [Side Effect], alanine aminotransferase/ec [Endogenous Compound], B Raf kinase/ec [Endogenous Compound], K ras protein/ec [Endogenous Compound], lifirafenib/ae [Adverse Drug Reaction], lifirafenib/ct [Clinical Trial], lifirafenib/cr [Drug Concentration], lifirafenib/do [Drug Dose], lifirafenib/dt [Drug Therapy], lifirafenib/to [Drug Toxicity], lifirafenib/pd [Pharmacology], dizziness/si [Side Effect], abdominal pain/si [Side Effect], adult, aged, alanine aminotransferase blood level, anemia/si [Side Effect], antineoplastic activity, arthralgia/si [Side Effect], article, backache/si [Side Effect], blood level, blood toxicity/si [Side Effect], body weight disorder/si [Side Effect], body weight loss, brain hemorrhage/si [Side Effect], cancer chemotherapy, cancer patient, cancer radiotherapy, cancer staging, cancer survival, chill/si [Side Effect], cohort analysis, colorectal cancer/di [Diagnosis], colorectal cancer/dt [Drug Therapy], colorectal cancer/et [Etiology], constipation/si [Side Effect], coughing/si [Side Effect], decreased appetite/si [Side Effect], dermatitis/si [Side Effect], diarrhea/si [Side Effect], disease exacerbation/si [Side Effect], drug blood level, drug dose increase, drug half life, drug safety, drug tolerability, dry skin/si [Side Effect], dysgeusia/si [Side Effect], dysphonia/si [Side Effect], dyspnea/si [Side Effect], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28975
Journal of Clinical Oncology
Click here for full text options
LibKey Link

المؤلفون: Wu C.-Y., Zhang Y., Liang L., Wu J., Paton V., Millward M., Keam B., Jameson M., Hou M.-M., Kang Y.-K., Markman B., Lu C.-H., Rau K.-M., Lee K.-H., Horvath L., Friedlander M., Hill A., Sandhu S., Barlow P., Desai J., Deva S., Lee J.S., Lin C.-C., Yen C.-J., Chao Y.

مصطلحات الفهرس: hypercalcemia/si [Side Effect], hyperglycemia/si [Side Effect], hypertransaminasemia/si [Side Effect], hypokalemia/si [Side Effect], hyponatremia/si [Side Effect], liver cell carcinoma/dt [Drug Therapy], loss of appetite/si [Side Effect], lower respiratory tract infection/si [Side Effect], lung embolism/si [Side Effect], major clinical study, male, maximum tolerated dose, melanoma/dt [Drug Therapy], merkel cell carcinoma/dt [Drug Therapy], microsatellite instability, monotherapy, multiple cycle treatment, nausea and vomiting/si [Side Effect], non small cell lung cancer/dt [Drug Therapy], optimal drug dose, ovary carcinoma/dt [Drug Therapy], pancreas cancer/dt [Drug Therapy], phase 1 clinical trial, pleura effusion/si [Side Effect], pneumonia/si [Side Effect], priority journal, rash/si [Side Effect], recommended drug dose, renal cell carcinoma/dt [Drug Therapy], retrospective study, sepsis/si [Side Effect], skin carcinoma/dt [Drug Therapy], small intestine obstruction/si [Side Effect], solid malignant neoplasm/dt [Drug Therapy], stomach cancer/dt [Drug Therapy], time to maximum plasma concentration, treatment response time, triple negative breast cancer/dt [Drug Therapy], upper gastrointestinal bleeding/si [Side Effect], bilirubin/ec [Endogenous Compound], new drug/ct [Clinical Trial], new drug/do [Drug Dose], new drug/dt [Drug Therapy], new drug/to [Drug Toxicity], new drug/iv [Intravenous Drug Administration], new drug/pk [Pharmacokinetics], new drug/pv [Special Situation for Pharmacovigilance], programmed death 1 ligand 1/ec [Endogenous Compound], tislelizumab/ae [Adverse Drug Reaction], tislelizumab/ct [Clinical Trial], tislelizumab/cr [Drug Concentration], tislelizumab/do [Drug Dose], tislelizumab/dt [Drug Therapy], tislelizumab/to [Drug Toxicity], tislelizumab/iv [Intravenous Drug Administration], tislelizumab/pk [Pharmacokinetics], tislelizumab/pv [Special Situation for Pharmacovigilance], tislelizumab/tm [Unexpected Outcome of Drug Treatment], immunohistochemical test kit, VENTANA PD-L1 (SP263), maximum concentration, adult, aged, anemia/si [Side Effect], antineoplastic activity, area under the curve, article, ascites/si [Side Effect], backache/si [Side Effect], bile duct carcinoma/dt [Drug Therapy], body weight disorder/si [Side Effect], clinical outcome, cohort analysis, colitis/si [Side Effect], colorectal cancer/dt [Drug Therapy], constipation/si [Side Effect], controlled study, coughing/si [Side Effect], diarrhea/si [Side Effect], drug dosage form comparison, drug dose escalation, drug dose regimen, drug efficacy, drug half life, drug safety, drug tolerability, drug withdrawal, dysphagia/si [Side Effect], dyspnea/si [Side Effect], esophagus cancer/dt [Drug Therapy], esophagus carcinoma/dt [Drug Therapy], fatigue/si [Side Effect], female, follow up, gastrointestinal stromal tumor/dt [Drug Therapy], head and neck squamous cell carcinoma/dt [Drug Therapy], human, hyperbilirubinemia/si [Side Effect], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29145
Journal for ImmunoTherapy of Cancer
Click here for full text options
LibKey Link

المؤلفون: Chew C.Y., Saracino A.M., Nikpour M., Mar A.

مصطلحات الفهرس: drug absorption, drug bioavailability, drug contraindication, drug efficacy, drug metabolism, drug safety, erythema annulare centrifugum/si [Side Effect], erythema multiforme/si [Side Effect], eye examination, gastrointestinal symptom/si [Side Effect], giant cell granuloma/dt [Drug Therapy], glioblastoma/dt [Drug Therapy], glucose 6 phosphate dehydrogenase deficiency, granuloma annulare/dt [Drug Therapy], heart protection, heartburn/si [Side Effect], human, hyperpigmentation/si [Side Effect], hypertransaminasemia/si [Side Effect], hypoglycemia/si [Side Effect], immunomodulation, irritability, leukopenia/si [Side Effect], lichen (disease)/dt [Drug Therapy], lichen planus/dt [Drug Therapy], lichen sclerosus et atrophicus/dt [Drug Therapy], liver toxicity/si [Side Effect], lung cancer/dt [Drug Therapy], lupus vulgaris/dt [Drug Therapy], measles like rash/si [Side Effect], melanoma/dt [Drug Therapy], mood change, morphea/dt [Drug Therapy], mucinosis/dt [Drug Therapy], multiple myeloma/dt [Drug Therapy], nausea/si [Side Effect], necrobiosis lipoidica/dt [Drug Therapy], nightmare/si [Side Effect], nonhuman, outcome assessment, pancreas cancer/dt [Drug Therapy], panniculitis/dt [Drug Therapy], patient monitoring, pharmacodynamics, photodermatosis/dt [Drug Therapy], porphyria cutanea tarda/dt [Drug Therapy], practice guideline, pregnancy, prescription, pruritus/si [Side Effect], psoriasis/si [Side Effect], rash/si [Side Effect], retina maculopathy/si [Side Effect], retinopathy/si [Side Effect], review, risk benefit analysis, risk reduction, sarcoma/dt [Drug Therapy], side effect/si [Side Effect], skin contusion/si [Side Effect], skin sarcoidosis/dt [Drug Therapy], smoking, solid malignant neoplasm/dt [Drug Therapy], Stevens Johnson syndrome/si [Side Effect], systemic lupus erythematosus/dt [Drug Therapy], systemic sclerosis/dt [Drug Therapy], toxic epidermal necrolysis/si [Side Effect], treatment response, urticaria/si [Side Effect], vasculitis/dt [Drug Therapy], visual impairment/si [Side Effect], vomiting/si [Side Effect], cyclosporine/it [Drug Interaction], digoxin/it [Drug Interaction], glucose 6 phosphate dehydrogenase/ec [Endogenous Compound], hydroxychloroquine/ae [Adverse Drug Reaction], hydroxychloroquine/it [Drug Interaction], hydroxychloroquine/dt [Drug Therapy], hydroxychloroquine/pk [Pharmacokinetics], hydroxychloroquine/pd [Pharmacology], methotrexate/it [Drug Interaction], follicular mucinosis/dt [Drug Therapy], lichen planopilaris/dt [Drug Therapy], reticular erythematous mucinosis/dt [Drug Therapy], urticarial vasculitis/dt [Drug Therapy], laboratory test, abdominal distension/si [Side Effect], acute generalized exanthematous pustulosis/si [Side Effect], agranulocytosis/si [Side Effect], alopecia/si [Side Effect], alopecia areata/dt [Drug Therapy], anorexia/si [Side Effect], antineoplastic activity, antiphospholipid syndrome/dt [Drug Therapy], antithrombotic activity, aplastic anemia/si [Side Effect], blood toxicity/si [Side Effect], chronic urticaria/dt [Drug Therapy], dermatology, dermatomyositis/dt [Drug Therapy], diarrhea/si [Side Effect], DRESS syndrome/si [Side Effect], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35375
Australasian Journal of Dermatology
Click here for full text options
LibKey Link

المؤلفون: Wu C.-Y., Zhang Y., Liang L., Wu J., Paton V., Millward M., Keam B., Jameson M., Hou M.-M., Kang Y.-K., Markman B., Lu C.-H., Rau K.-M., Lee K.-H., Horvath L., Friedlander M., Hill A., Sandhu S., Barlow P., Desai J., Deva S., Lee J.S., Lin C.-C., Yen C.-J., Chao Y.

مصطلحات الفهرس: hypercalcemia/si [Side Effect], hyperglycemia/si [Side Effect], hypertransaminasemia/si [Side Effect], hypokalemia/si [Side Effect], hyponatremia/si [Side Effect], liver cell carcinoma/dt [Drug Therapy], loss of appetite/si [Side Effect], lower respiratory tract infection/si [Side Effect], lung embolism/si [Side Effect], major clinical study, male, maximum tolerated dose, melanoma/dt [Drug Therapy], merkel cell carcinoma/dt [Drug Therapy], microsatellite instability, monotherapy, multiple cycle treatment, nausea and vomiting/si [Side Effect], non small cell lung cancer/dt [Drug Therapy], optimal drug dose, ovary carcinoma/dt [Drug Therapy], pancreas cancer/dt [Drug Therapy], phase 1 clinical trial, pleura effusion/si [Side Effect], pneumonia/si [Side Effect], priority journal, rash/si [Side Effect], recommended drug dose, renal cell carcinoma/dt [Drug Therapy], retrospective study, sepsis/si [Side Effect], skin carcinoma/dt [Drug Therapy], small intestine obstruction/si [Side Effect], solid malignant neoplasm/dt [Drug Therapy], stomach cancer/dt [Drug Therapy], time to maximum plasma concentration, treatment response time, triple negative breast cancer/dt [Drug Therapy], upper gastrointestinal bleeding/si [Side Effect], bilirubin/ec [Endogenous Compound], new drug/ct [Clinical Trial], new drug/do [Drug Dose], new drug/dt [Drug Therapy], new drug/to [Drug Toxicity], new drug/iv [Intravenous Drug Administration], new drug/pk [Pharmacokinetics], new drug/pv [Special Situation for Pharmacovigilance], programmed death 1 ligand 1/ec [Endogenous Compound], tislelizumab/ae [Adverse Drug Reaction], tislelizumab/ct [Clinical Trial], tislelizumab/cr [Drug Concentration], tislelizumab/do [Drug Dose], tislelizumab/dt [Drug Therapy], tislelizumab/to [Drug Toxicity], tislelizumab/iv [Intravenous Drug Administration], tislelizumab/pk [Pharmacokinetics], tislelizumab/pv [Special Situation for Pharmacovigilance], tislelizumab/tm [Unexpected Outcome of Drug Treatment], immunohistochemical test kit, VENTANA PD-L1 (SP263), maximum concentration, adult, aged, anemia/si [Side Effect], antineoplastic activity, area under the curve, article, ascites/si [Side Effect], backache/si [Side Effect], bile duct carcinoma/dt [Drug Therapy], body weight disorder/si [Side Effect], clinical outcome, cohort analysis, colitis/si [Side Effect], colorectal cancer/dt [Drug Therapy], constipation/si [Side Effect], controlled study, coughing/si [Side Effect], diarrhea/si [Side Effect], drug dosage form comparison, drug dose escalation, drug dose regimen, drug efficacy, drug half life, drug safety, drug tolerability, drug withdrawal, dysphagia/si [Side Effect], dyspnea/si [Side Effect], esophagus cancer/dt [Drug Therapy], esophagus carcinoma/dt [Drug Therapy], fatigue/si [Side Effect], female, follow up, gastrointestinal stromal tumor/dt [Drug Therapy], head and neck squamous cell carcinoma/dt [Drug Therapy], human, hyperbilirubinemia/si [Side Effect], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29145
Journal for ImmunoTherapy of Cancer
LibKey Link

المؤلفون: Atkinson V., Haydon A., Millward M., Begbie S., Brown M., Markman B., Patterson W., Hill A., Horvath L., Nagrial A., Richardson G., Jackson C., Friedlander M., Parente P., Tran B., Wang L., Chen Y., Tang Z., Huang W., Wu J., Zeng D., Luo L., Solomon B., Desai J., Gan H., Barrow C., Jameson M.

مصطلحات الفهرس: endometrium cancer/di [Diagnosis], endometrium cancer/dt [Drug Therapy], endometrium cancer/et [Etiology], enzyme inhibition, fatigue/si [Side Effect], female, fever/si [Side Effect], gastroesophageal reflux/si [Side Effect], glossodynia/si [Side Effect], hand foot syndrome/si [Side Effect], headache/si [Side Effect], human, hyperkeratosis/si [Side Effect], hypertension/si [Side Effect], hypomagnesemia/si [Side Effect], hypophosphatemia/si [Side Effect], hypotension/si [Side Effect], insomnia/si [Side Effect], intestine obstruction/si [Side Effect], intestine perforation/si [Side Effect], lethargy/si [Side Effect], limb pain/si [Side Effect], major clinical study, male, maximum plasma concentration, maximum tolerated dose, melanoma/di [Diagnosis], melanoma/dt [Drug Therapy], melanoma/et [Etiology], multiple cycle treatment, muscle spasm/si [Side Effect], musculoskeletal chest pain/si [Side Effect], myalgia/si [Side Effect], nausea/si [Side Effect], neutropenia/si [Side Effect], non small cell lung cancer/di [Diagnosis], non small cell lung cancer/dt [Drug Therapy], non small cell lung cancer/et [Etiology], oncogene N ras, oropharynx pain/si [Side Effect], ovary cancer/di [Diagnosis], ovary cancer/dt [Drug Therapy], ovary cancer/et [Etiology], palmoplantar keratoderma/si [Side Effect], pericardial effusion/si [Side Effect], phase 1 clinical trial, photosensitivity/si [Side Effect], pleura effusion/si [Side Effect], positron emission tomography-computed tomography, priority journal, progression free survival, pruritus/si [Side Effect], QT prolongation/si [Side Effect], rash/si [Side Effect], sepsis/si [Side Effect], side effect/si [Side Effect], skin defect/si [Side Effect], skin hypertrophy/si [Side Effect], solid malignant neoplasm, thrombocytopenia/si [Side Effect], thrush/si [Side Effect], thyroid cancer/di [Diagnosis], thyroid cancer/dt [Drug Therapy], thyroid cancer/et [Etiology], thyroid papillary carcinoma/di [Diagnosis], thyroid papillary carcinoma/dt [Drug Therapy], thyroid papillary carcinoma/et [Etiology], treatment duration, upper abdominal pain/si [Side Effect], upper respiratory tract infection/si [Side Effect], urinary tract infection/si [Side Effect], vomiting/si [Side Effect], xerostomia/si [Side Effect], alanine aminotransferase/ec [Endogenous Compound], B Raf kinase/ec [Endogenous Compound], K ras protein/ec [Endogenous Compound], lifirafenib/ae [Adverse Drug Reaction], lifirafenib/ct [Clinical Trial], lifirafenib/cr [Drug Concentration], lifirafenib/do [Drug Dose], lifirafenib/dt [Drug Therapy], lifirafenib/to [Drug Toxicity], lifirafenib/pd [Pharmacology], dizziness/si [Side Effect], abdominal pain/si [Side Effect], adult, aged, alanine aminotransferase blood level, anemia/si [Side Effect], antineoplastic activity, arthralgia/si [Side Effect], article, backache/si [Side Effect], blood level, blood toxicity/si [Side Effect], body weight disorder/si [Side Effect], body weight loss, brain hemorrhage/si [Side Effect], cancer chemotherapy, cancer patient, cancer radiotherapy, cancer staging, cancer survival, chill/si [Side Effect], cohort analysis, colorectal cancer/di [Diagnosis], colorectal cancer/dt [Drug Therapy], colorectal cancer/et [Etiology], constipation/si [Side Effect], coughing/si [Side Effect], decreased appetite/si [Side Effect], dermatitis/si [Side Effect], diarrhea/si [Side Effect], disease exacerbation/si [Side Effect], drug blood level, drug dose increase, drug half life, drug safety, drug tolerability, dry skin/si [Side Effect], dysgeusia/si [Side Effect], dysphonia/si [Side Effect], dyspnea/si [Side Effect], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28975
Journal of Clinical Oncology
LibKey Link

المؤلفون: Chew C.Y., Saracino A.M., Nikpour M., Mar A.

مصطلحات الفهرس: drug absorption, drug bioavailability, drug contraindication, drug efficacy, drug metabolism, drug safety, erythema annulare centrifugum/si [Side Effect], erythema multiforme/si [Side Effect], eye examination, gastrointestinal symptom/si [Side Effect], giant cell granuloma/dt [Drug Therapy], glioblastoma/dt [Drug Therapy], glucose 6 phosphate dehydrogenase deficiency, granuloma annulare/dt [Drug Therapy], heart protection, heartburn/si [Side Effect], human, hyperpigmentation/si [Side Effect], hypertransaminasemia/si [Side Effect], hypoglycemia/si [Side Effect], immunomodulation, irritability, leukopenia/si [Side Effect], lichen (disease)/dt [Drug Therapy], lichen planus/dt [Drug Therapy], lichen sclerosus et atrophicus/dt [Drug Therapy], liver toxicity/si [Side Effect], lung cancer/dt [Drug Therapy], lupus vulgaris/dt [Drug Therapy], measles like rash/si [Side Effect], melanoma/dt [Drug Therapy], mood change, morphea/dt [Drug Therapy], mucinosis/dt [Drug Therapy], multiple myeloma/dt [Drug Therapy], nausea/si [Side Effect], necrobiosis lipoidica/dt [Drug Therapy], nightmare/si [Side Effect], nonhuman, outcome assessment, pancreas cancer/dt [Drug Therapy], panniculitis/dt [Drug Therapy], patient monitoring, pharmacodynamics, photodermatosis/dt [Drug Therapy], porphyria cutanea tarda/dt [Drug Therapy], practice guideline, pregnancy, prescription, pruritus/si [Side Effect], psoriasis/si [Side Effect], rash/si [Side Effect], retina maculopathy/si [Side Effect], retinopathy/si [Side Effect], review, risk benefit analysis, risk reduction, sarcoma/dt [Drug Therapy], side effect/si [Side Effect], skin contusion/si [Side Effect], skin sarcoidosis/dt [Drug Therapy], smoking, solid malignant neoplasm/dt [Drug Therapy], Stevens Johnson syndrome/si [Side Effect], systemic lupus erythematosus/dt [Drug Therapy], systemic sclerosis/dt [Drug Therapy], toxic epidermal necrolysis/si [Side Effect], treatment response, urticaria/si [Side Effect], vasculitis/dt [Drug Therapy], visual impairment/si [Side Effect], vomiting/si [Side Effect], cyclosporine/it [Drug Interaction], digoxin/it [Drug Interaction], glucose 6 phosphate dehydrogenase/ec [Endogenous Compound], hydroxychloroquine/ae [Adverse Drug Reaction], hydroxychloroquine/it [Drug Interaction], hydroxychloroquine/dt [Drug Therapy], hydroxychloroquine/pk [Pharmacokinetics], hydroxychloroquine/pd [Pharmacology], methotrexate/it [Drug Interaction], follicular mucinosis/dt [Drug Therapy], lichen planopilaris/dt [Drug Therapy], reticular erythematous mucinosis/dt [Drug Therapy], urticarial vasculitis/dt [Drug Therapy], laboratory test, abdominal distension/si [Side Effect], acute generalized exanthematous pustulosis/si [Side Effect], agranulocytosis/si [Side Effect], alopecia/si [Side Effect], alopecia areata/dt [Drug Therapy], anorexia/si [Side Effect], antineoplastic activity, antiphospholipid syndrome/dt [Drug Therapy], antithrombotic activity, aplastic anemia/si [Side Effect], blood toxicity/si [Side Effect], chronic urticaria/dt [Drug Therapy], dermatology, dermatomyositis/dt [Drug Therapy], diarrhea/si [Side Effect], DRESS syndrome/si [Side Effect], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35375
Australasian Journal of Dermatology
LibKey Link